)

Seer (SEER) investor relations material
Seer Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Product innovation and platform evolution
Released third-generation Proteograph One in June 2025, enabling large-scale, unbiased proteomics at improved speed and cost.
Proteograph One doubles throughput to 1,000 samples per week and reduces runtime by 30% compared to XT.
New SP200 instrument and Proteograph Direct Assay introduced, offering end-to-end proprietary workflow and automation for both complex and less complex samples.
Workflow improvements include halved MassTech time, reduced manual steps, and better cost efficiency, leading to higher margins.
Direct Assay broadens instrument utility, allowing cell and tissue analysis without proprietary particles, addressing customer needs for automation.
Market adoption and customer trends
Shift from small proof-of-principle studies to immediate large-scale adoption, with customers now starting with thousands of samples.
Announced major studies: 10,000-sample corporate study, 20,000-sample Korea University study, and a 10,000-sample pilot with a biobank aiming for 100,000 samples.
Customers value reproducibility, robustness, and scalability for longitudinal and multi-site studies, leading to selection over competitors.
Comparative studies published by customers highlight superior performance over lower-cost, me-too platforms.
Expectation that population-scale studies will become more common, with 2026 predicted as the year for the first 100,000-sample unbiased proteomics study.
Competitive landscape and differentiation
Proteomics market divided into targeted (e.g., OLINK, SomaLogic) and untargeted approaches, with Seer positioned as a leader in untargeted, large-scale discovery.
Targeted and untargeted platforms seen as complementary; untargeted needed for discovery, targeted for clinical applications.
Me-too nanoparticle-based platforms lack depth, reproducibility, and robustness, causing customer confusion but not real competition.
Customers prioritize data quality and sample value over lower assay costs, especially in high-value biopharma applications.
Future differentiation will depend on ability to deliver from discovery to clinical, with untargeted approaches driving innovation.
Next Seer earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage